Abnova (Taiwan)TPE:4133 -1.46%75 EBITDA Margin % is 24.35% as of Dec. 2025, which is 17% above its 10-year median of 20.78. GuruFocus rates TPE:4133 with a GF Score™ of 75/100 and a GF Value™ of NT$28.30 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, Abnova (Taiwan) ranks better than 72.99% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Abnova (Taiwan)'s EBITDA for the
three
months ended in Dec. 2025 was NT$20.4 Mil. Abnova (Taiwan)'s Revenue for the
three
months ended in Dec. 2025 was NT$83.9 Mil. Therefore, Abnova (Taiwan)'s EBITDA margin for the quarter that ended in Dec. 2025 was 24.35%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Abnova (Taiwan) EBITDA Margin % Related Terms
Abnova (Taiwan) EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Abnova (Taiwan)'s EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4133 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Abnova (Taiwan)'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abnova (Taiwan) EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abnova (Taiwan)'s EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Abnova (Taiwan)'s EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abnova (Taiwan) (TPE:4133) has a EBITDA Margin % of 24.35% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Abnova (Taiwan) and its competitors. This is 17% above median its historical median of 20.78. Over the past decade, Abnova (Taiwan)'s EBITDA Margin % has ranged from 7.69 to 31.48. According to the industry distribution chart, Abnova (Taiwan) ranks #255 out of 944 companies in the Biotechnology industry, placing it in the top 27%.
Is Abnova (Taiwan)'s EBITDA Margin % too high?
Abnova (Taiwan)'s current EBITDA Margin % of 24.35% is 17% above median its 10-year median of 20.78. Over the past 10 years, this metric has ranged from a low of 7.69 to a high of 31.48. Based on the distribution chart, Abnova (Taiwan) ranks #255 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Abnova (Taiwan) has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abnova (Taiwan)'s EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abnova (Taiwan) ranks #255 out of 944 companies for EBITDA Margin %. This puts Abnova (Taiwan) in the upper half of its industry. Historically, Abnova (Taiwan)'s own EBITDA Margin % has ranged from 7.69 to 31.48 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Abnova (Taiwan) and its competitors. Abnova (Taiwan)'s current EBITDA Margin % is 24.35%, which is 17% above median its own 10-year median of 20.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abnova (Taiwan) stock overvalued right now?
Based on GuruFocus' analysis, Abnova (Taiwan) (TPE:4133) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$28.30, compared to a current price of NT$20.25 — trading 28.4% below its estimated fair value. The current EBITDA Margin % is 24.35%, which is 17% above median its 10-year median of 20.78. Abnova (Taiwan)'s overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Abnova (Taiwan) (TPE:4133), the current EBITDA Margin % is 24.35% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abnova (Taiwan) (TPE:4133) Overvalued in 2026?
Based on GuruFocus' analysis, Abnova (Taiwan) stock appears to be undervalued.
The current stock price of NT$20.25 is trading 28.4% below its estimated GF Value™ of NT$28.30.
GuruFocus considers Abnova (Taiwan) to be Modestly Undervalued.
Key valuation signals for TPE:4133:
EBITDA Margin %: 24.35% (17% above median its 10-year median of 20.78)
GF Value™: NT$28.30 vs. price of NT$20.25 (28.4% below fair value)
No single metric tells the full story. See the TPE:4133 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abnova (Taiwan) Corp is engaged in developing, manufacturing, and selling monoclonal antibody, polyclonal antibody, proteins, medical inspection instruments and testing reagents, which are mainly antibody reagents, antibody chips or related products provided to and used by academic, research institutions or pharmaceutical factories. Geographically, it operates in America, Europe, Taiwan and Other Countries. It generates maximum revenue from America. Its products include: SARS-CoV/CoV-2, DNA, RNA new, Proteins/peptides, MaxPab, DNAxPab, Polyclonal Ab, Monoclonal Ab and Others. The company's services are: Gene synthesis & cytogenetics, Peptide services, Protein expression, Humanized antibody, Assay development, Conjugation, FFPE tumor tissue DNA, In situ hybridization (ISH) and Others.
75GF Score
Get the complete analysis for TPE:4133
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4133 has been successfully added to your 
